Verastem, Inc., a development-stage biopharmaceutical company based in Needham, Massachusetts, has recently disclosed changes in the holdings of its top executives through Form 4 reports filed on October 2, 2026. The company, which specializes in the development and commercialization of medicines and treatments for cancer and tumor growth, particularly targeting RAF, MEK, and focal adhesion kinase (FAK) inhibition, serves patients and healthcare professionals in the United States. Listed on the Nasdaq stock exchange, Verastem, Inc. has a market capitalization of $715.45 million as of October 1, 2026, with a close price of $7.70. The company’s 52-week high was $10.82 on November 25, 2025, and its 52-week low was $3.43 on June 24, 2026. The price-to-earnings ratio stands at -3.3.
The Form 4 filings detail the vesting of performance-restricted stock units for President and CEO Daniel Paterson and Chief Financial Officer Daniel Calkins. Both executives reported the vesting of these awards on September 30, 2026, with subsequent sales of a portion of the newly vested shares on October 1, 2026, to satisfy withholding obligations. The awards, granted on January 21, 2026, were tied to clinical development milestones, which have been met. The filings provide information on the number of shares acquired and sold, the remaining holdings after each transaction, and the relationship of each officer to the company. No additional material events or disclosures were included in these filings.
Verastem, Inc. continues to focus on its mission to develop innovative treatments for cancer, leveraging its expertise in RAF, MEK, and FAK inhibition. The company’s efforts are aimed at addressing unmet medical needs in oncology, with a commitment to advancing its pipeline of potential therapies. As Verastem progresses through its clinical development phases, the company remains dedicated to delivering value to its shareholders and improving outcomes for patients with cancer.
